Upgrade to SI Premium - Free Trial

Barclays reiterates Overweight on Incyte (INCY) despite mixed Ph3 trial results

March 24, 2026 4:02 PM
Barclays analyst Etzer Darout reiterated an Overweight rating and $117.00 price target on Incyte (NASDAQ: INCY)The analyst commented, "SVR35 endpoint ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments